SuperNova Inks Deal with KSB to Expand Diagnostic Business into China
Agreement covers R&D, manufacturing, and commercialization.!--h2>
SuperNova Diagnostics® will expand into China under an agreement with in vitro diagnostic kit maker Shenzhen Kang Sheng Bao Bio-Technology (KSB). "This collaborative relationship allows SuperNova and KSB to expand R&D, manufacturing, and commercialization into one of the world's largest markets," points out Neil Campbell, president and CEO of SuperNova Diagnostics.
KSB specializes in research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and affiliated markets. SuperNova focuses on detecting pathogens that lead to enteric and diarrheal diseases, malaria, tuberculosis, influenza, and other infectious diseases for humans. It also develops diagnostics for food and water safety as well as animal health.
SuperNova’s lead technology, AmpCrystal®, consists of hyper-dense, energy-mediated nanocrystals designed to let individuals without CLIA training test for a range of protein analytes and directly detect unamplified DNA in humans, animals, or environmental samples. The company says that the technology promises results in minutes.
AmpCrystal is used in multiple diagnostic formats including lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products, and OEM. It can reportedly be integrated into current diagnostic formats.